WO2010065815A2 - Mini-hepcidin peptides and methods of using thereof - Google Patents
Mini-hepcidin peptides and methods of using thereof Download PDFInfo
- Publication number
- WO2010065815A2 WO2010065815A2 PCT/US2009/066711 US2009066711W WO2010065815A2 WO 2010065815 A2 WO2010065815 A2 WO 2010065815A2 US 2009066711 W US2009066711 W US 2009066711W WO 2010065815 A2 WO2010065815 A2 WO 2010065815A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pro
- cys
- peptide
- amino acid
- phe
- Prior art date
Links
- 0 CC1C(C)C*CC1 Chemical compound CC1C(C)C*CC1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention generally relates to peptides which exhibit hepcidin activity.
- Hepcidin a peptide hormone produced by the liver, is a regulator of iron homeostasis in humans and other mammals. Hepcidin acts by binding to its receptor, the iron export channel ferroportin, and causing its internalization and degradation.
- Human hepcidin is a 25-amino acid peptide (Hep25). See Rrause et al. (2000) FEBS Lett 480:147-150, and Park et al. (2001) J Biol Chem 276:7806-7810.
- the structure of the bioactive 25-amino acid form of hepcidin is a simple hairpin with 8 cysteines that form 4 disulfide bonds as described by Jordan et al.
- HH hereditary hemochromatosis
- iron overload diseases which include hereditary hemochromatosis and iron-loading anemias.
- Hereditary hemochromatosis (HH) is a genetic iron overload disease that is mainly caused by hepcidin deficiency, or very rarely by hepcidin resistance. This allows excessive absorption of iron from the diet and development of iron overload.
- Clinical manifestations of HH may include liver disease (hepatic cirrhosis, hepatocellular carcinoma), diabetes, and heart failure.
- liver disease hepatic cirrhosis, hepatocellular carcinoma
- diabetes hepatocellular carcinoma
- heart failure Currently, the only treatment for HH is regular phlebotomy, which is effective but very burdensome for the patients.
- Iron- loading anemias are hereditary anemias with ineffective erythropoiesis such as ⁇ -thalassemia, which are accompanied by severe iron overload. Complications from iron overload are the main cause of morbidity and mortality for these patients. Hepcidin deficiency is the main cause of iron overload in untransfused patients, and contributes to iron overload in transfused patients. The current treatment for iron overload in these patients is iron chelation which is very burdensome, sometimes ineffective and accompanied by frequent side effects.
- the present invention generally relates to peptides which exhibit hepcidin activity and methods of using thereof.
- the present invention provides peptides, which may be isolated and/or purified, comprising, consisting essentially or consisting of the following structural formula
- Al is Asp, GIu, pyroglutamate, GIn, Asn, or an unnatural amino acid commonly used as a substitute thereof;
- A2 is Thr, Ser, VaI, Ala or an unnatural amino acid commonly used as a substitute thereof;
- A3 is His, Asn, Arg, or an unnatural amino acid commonly used as a substitute thereof;
- A4 is Phe, Leu, He, Trp, Tyr or an unnatural amino acid commonly used as a substitute thereof which includes cyclohexylalanine;
- A5 is Pro, Ser, or an unnatural amino acid commonly used as a substitute thereof;
- A6 is He, Leu, VaI, or an unnatural amino acid commonly used as a substitute thereof;
- A7 is Cys, Ser, Ala, or an unnatural amino acid commonly used as a substitute thereof which includes S-tertiary butyl-cysteine;
- A8 is He, Leu, Thr, VaI, Arg, or an unnatural amino acid commonly used
- A9 is Phe, Leu, He, Tyr or an unnatural amino acid commonly used as a substitute thereof which includes cyclohexylalanine; and AlO is Cys, Ser, Ala, or an unnatural amino acid commonly used as a substitute thereof; wherein the carboxy-terminal amino acid is in amide or carboxy- form; wherein at least one sulfhydryl amino acid is present as one of the amino acids in the sequence; and wherein Al, A2, A3, Al to A2, Al to A3, AlO, A9 to AlO, A8 to AlO, or a combination thereof are optionally absent, with the proviso that the peptide does not consist of amino acid residues 1 to 6 ofHep25.
- the peptides of the present invention are not Hep4-7,
- the peptides of the present invention contain only one amino acid residue having a thiol capable of forming a disulfide bond.
- the peptides of the present invention contain only two amino acid residues which each have a thiol capable of forming a disulfide bond. [18] In some embodiments,
- Al is D-Asp, D-GIu, D-pyroglutamate, D-GIn, D-Asn, bbAsp, Ida, or N-
- A2 is D-Thr, D-Ser, D-VaI, Tie, Inp, Chg, bhThr, or N-MeThr;
- A3 is D-His, D-Asn, DArg, Dpa, (D)Dpa, or 2-aminoindan;
- A4 is D-Phe, D-Leu, D-IIe, D-Trp, Phg, bhPhe, Dpa, Bip, INaI, bhDpa, Amc,
- A5 is D-Pro, D-Ser, Oic, bhPro, trans-4-PhPro, cis-4-PhPro, cis-5-PhPro, Idc;
- A6 is D-IIe, D-Leu, Phg, Chg, Amc, bhlle, Ach, and MeIIe;
- A7 is D-Cys, D-Ser, D-AIa, Cys(S-tBut), homoC, Pen, (D)Pen, Dap(AcBr), and Inp;
- A8 is D-IIe, D-Leu, D-Thr, D-VaI, D-Arg, Chg, Dpa, bhlle, Ach, or MeIIe;
- A9 is D-Phe, D-Leu, D-IIe, PheF5, N-MePhe, benzylamide, bhPhe, Dpa, Bip,
- AlO is D-Cys, D-Ser, D-AIa; or a combination thereof.
- Al is Ala, D-AIa, Cys, D-Cys, Phe, D-Phe, Asp or D-Asp linked to Cys or D- Cys, Phe or D-Phe linked to a PEG molecule linked to chenodeoxycholate, ursodeoxycholate, or palmitoyl, or Dpa or (D)Dpa linked to palmitoyl;
- A2 is Ala, D-AIa, Cys, D-Cys, Pro, D-Pro, GIy, or D-GIy;
- A3 is Ala, D-AIa, Cys, D-Cys, Dpa, Asp or D-Asp linked to Dpa or (D)Dpa;
- A4 is Ala, D-AIa, Pro, or D-Pro;
- A5 is Ala, D-AIa, Pro, D-Pro, Arg, D-Arg;
- A6 is Ala, D-AIa, Phe, D-Phe, Arg, D-Arg, Cys, D-Cys;
- A7 is His, or D-His;
- A8 is Cys, or D-Cys; or
- A9 is Phe or D-Phe linked to RA, Asp, D-Asp, Asp or D-Asp linked to RB, bhPhe linked to RC, or cysteamide, wherein RA is -CONH 2 -CH 2 -CH 2 -S, -D-Pro linked to Pro-Lys or Pro-Arg, -bhPro linked to Pro linked to Pro- Lys or Pro-Arg, -D-Pro linked to bhPro-Lys or bhPro-Arg, wherein RB is -PEGU -GYIPEAPRDGQAYVRKDGEWVLLSTFL, -(PEGI l)- (GPHyp)lO, and wherein RC is -D-Pro linked to Pro-Lys or Pro-Arg, -D- Pro linked to bhPro-Lys or bhPro-Arg; or a combination thereof.
- A6 is He; A7 is Ala; A8 is He; A9 is Phe; and AlO is Cys in amide form; wherein Al or Al to A2 are optionally absent.
- Al is Asp
- A2 is Thr
- A3 is His
- A4 is Phe
- A5 is Pro
- A6 is He
- A7 is Cys or an unnatural thiol amino acid
- A8 is He
- A9 is Phe in amide form
- AlO is absent.
- Al and A2 are absent, A3 is His, A4 is Phe, A5 is Pro,
- A6 is He
- A7 is Cys or an unnatural thiol amino acid
- A8 is He in amide form
- A9 and AlO are absent.
- Al and A2 are absent, A3 is His, A4 is Phe, A5 is Pro,
- A6 is He
- A7 is Cys or an unnatural thiol amino acid in amide form
- A8 to AlO are absent.
- the peptides are cyclic peptides.
- the peptides are retroinverted such that Al is the amidated C-terminus and AlO is the N-terminus, and all amino acids are D-amino acids instead of the natural L-amino acids.
- the peptides have an addition at the N-terminus, C- terminus, or both.
- the peptides are selected from the group consisting of:
- the peptides exhibit hepcidin activity. In some embodiments, the peptides bind ferroportin, preferably human ferroportin.
- the present invention provides compositions and medicaments which comprise at least one peptide as disclosed herein.
- the present invention provides method of manufacturing medicaments for the treatment of diseases of iron metabolism, such as iron overload diseases, which comprise at least one peptide as disclosed herein.
- methods of treating a diseases of iron metabolism in a subject such as a mammalian subject, preferably a human subject, which comprises administering at least one peptide or composition as disclosed herein to the subject.
- the peptide is administered in a therapeutically effective amount.
- the present invention provides methods of binding a ferroportin or inducing ferroportin internalization and degradation which comprises contacting the ferroportin with at least one peptide or composition as disclosed herein.
- kits comprising at least one peptide or composition as disclosed herein packaged together with a reagent, a device, instructional material, or a combination thereof.
- the present invention provides complexes which comprise at least one peptide as disclosed herein bound to a ferroportin, preferably a human ferroportin, or an antibody, such as an antibody which specifically binds a peptide as disclosed herein, Hep25, or a combination thereof.
- Figure 1 is a graph showing the relative hepcidin activity of alanine substitutions in Hep25.
- Figure 2 A is a graph showing the relative hepcidin activities of F4 substitutions in Hep25.
- Figure 2B is a graph showing the relative hepcidin activities of F9 substitutions in Hep25.
- Figure 3 A is a graph showing the hepcidin activities of Hep 1-9 and Hepl-10
- Figure 3B is a graph showing the hepcidin activities of Hep 1-7 and Hep 1-8 relative to Hep 1-9 or Hep25.
- Figure 3C is a graph showing the hepcidin activities of Hep4-7, Hep3-7,
- Figure 4 is a graph showing the hepcidin activities of C7 modified peptides relative to Hep25.
- Figure 5 is a graph showing in vivo effect (as measured by serum iron levels in mice) of mini-hepcidins Hep 1-9, Pr6 and Pr 12 compared to Hep25 or control
- FIG. 6 is a graph showing in vivo effect (as measured by serum iron levels in mice) of mini-hepcidin Pr27 injected intraperitoneally (20 and 200 nmoles). The amount of injected Hep25 was 20 nmoles.
- Figure 7 is a graph showing in vivo effect (as measured by serum iron levels in mice) of mini-hepcidin riHep7 ⁇ DT injected intraperitoneally (20 and 200 nmoles).
- FIG. 8 is a graph showing in vivo effect (as measured by serum iron levels in mice) of mini-hepcidins Pr27 and Pr28 which were first mixed with liposomes and injected intraperitoneally (20 nmoles). The amount of injected Hep25 was 20 nmoles.
- Figure 9 is a graph showing in vivo effect (as measured by serum iron levels in mice) of mini-hepcidin Pr27 after oral administration by gavage (200 nmoles).
- the present invention provides peptides which are useful in the study and treatment of diseases of iron metabolism.
- a "disease of iron metabolism” includes diseases where aberrant iron metabolism directly causes the disease, or where iron blood levels are dysregulated causing disease, or where iron dysregulation is a consequence of another disease, or where diseases can be treated by modulating iron levels, and the like. More specifically, a disease of iron metabolism according to this disclosure includes iron overload diseases, iron deficiency disorders, disorders of iron biodistribution, other disorders of iron metabolism and other disorders potentially related to iron metabolism, etc.
- Diseases of iron metabolism include hemochromatosis, HFE mutation hemochromatosis, ferroportin mutation hemochromatosis, transferrin receptor 2 mutation hemochromatosis, hemojuvelin mutation hemochromatosis, hepcidin mutation hemochromatosis, juvenile hemochromatosis, neonatal hemochromatosis, hepcidin deficiency, transfusional iron overload, thalassemia, thalassemia intermedia, alpha thalassemia, sideroblastic anemia, porphyria, porphyria cutanea tarda, African iron overload, hyperferritinemia, ceruloplasmin deficiency, atransferrinemia, congenital dyserythropoietic anemia, anemia of chronic disease, anemia of inflammation, anemia of infection, hypochromic microcytic anemia, iron- deficiency anemia, iron-refractory iron deficiency anemia, anemia of chronic kidney disease, erythropoietin resistance, iron
- the diseases and disorders included in the definition of "disease of iron metabolism” are not typically identified as being iron related.
- hepcidin is highly expressed in the murine pancreas suggesting that diabetes (Type I or Type II), insulin resistance, glucose intolerance and other disorders may be ameliorated by treating underlying iron metabolism disorders.
- diabetes Type I or Type II
- insulin resistance insulin resistance
- glucose intolerance glucose intolerance
- other disorders may be ameliorated by treating underlying iron metabolism disorders. See Ilyin, G. et al. (2003) FEBS Lett. 542 22-26, which is herein incorporated by reference. As such, these diseases are encompassed under the broad definition.
- the diseases of iron metabolism are iron overload diseases, which include hereditary hemochromatosis, iron-loading anemias, alcoholic liver diseases and chronic hepatitis C.
- the terms "protein”, “polypeptide” and “peptide” are used interchangeably to refer to two or more amino acids linked together. Except for the abbreviations for the uncommon or unnatural amino acids set forth in Table 2 below, the three-letter and one-letter abbreviations, as used in the art, are used herein to represent amino acid residues. Except when preceded with "D-", the amino acid is an L-amino acid. Groups or strings of amino acid abbreviations are used to represent peptides. Except when specifically indicated, peptides are indicated with the N- terminus on the left and the sequence is written from the N-terminus to the C- terminus.
- the peptides of the present invention may be made using methods known in the art including chemical synthesis, biosynthesis or in vitro synthesis using recombinant DNA methods, and solid phase synthesis. See e.g. Kelly & Winkler (1990) Genetic Engineering Principles and Methods, vol. 12, J. K. Setlow ed., Plenum Press, NY, pp. 1-19; Merrif ⁇ eld (1964) J Amer Chem Soc 85:2149; Houghten (1985) PNAS USA 82:5131-5135; and Stewart & Young (1984) Solid Phase Peptide Synthesis, 2ed. Pierce, Rockford, IL, which are herein incorporated by reference.
- the peptides of the present invention may be purified using protein purification techniques known in the art such as reverse phase high-performance liquid chromatography (HPLC), ion-exchange or immunoaffmity chromatography, filtration or size exclusion, or electrophoresis. See Olsnes, S. and A. Pihl (1973) Biochem. 12(16):3121-3126; and Scopes (1982) Protein Purification, Springer- Verlag, NY, which are herein incorporated by reference.
- the peptides of the present invention may be made by recombinant DNA techniques known in the art.
- polynucleotides that encode the polypeptides of the present invention are contemplated herein.
- the polynucleotides are isolated.
- isolated polynucleotides refers to polynucleotides that are in an environment different from that in which the polynucleotide naturally occurs.
- the peptides of the present invention are substantially purified.
- a “substantially purified” compound refers to a compound that is removed from its natural environment and is at least about 60% free, preferably about 75% free, and most preferably about 90% free from other macromolecular components with which the compound is naturally associated.
- an "isolated" compound refers to a compound which is isolated from its native environment.
- an isolated peptide is a one which does not have its native amino acids, which correspond to the full length polypeptide, flanking the N-terminus, C-terminus, or both.
- isolated Hep 1-9 refers to an isolated peptide comprising amino acid residues 1-9 of Hep25 which may have non-native amino acids at its N-terminus, C-terminus, or both, but does not have a cysteine amino acid residue following its 9 th amino acid residue at the C-terminus.
- references to amino acid positions correspond to the amino acid residues of Hep25.
- reference to amino acid position 9 corresponds to the 9 th amino acid residue of Hep25.
- the peptides of the present invention bind ferroportin, preferably human ferroportin.
- Preferred peptides of the present invention specifically bind human ferroportin.
- "specifically binds" refers to a specific binding agent's preferential interaction with a given ligand over other agents in a sample.
- a specific binding agent that specifically binds a given ligand binds the given ligand, under suitable conditions, in an amount or a degree that is observable over that of any nonspecific interaction with other components in the sample.
- suitable conditions are those that allow interaction between a given specific binding agent and a given ligand. These conditions include pH, temperature, concentration, solvent, time of incubation, and the like, and may differ among given specific binding agent and ligand pairs, but may be readily determined by those skilled in the art.
- Hep25 the bioactive human 25-amino acid form
- mini- hepcidins are herein referred to as "mini- hepcidins”.
- a compound having "hepcidin activity” means that the compound has the ability to lower plasma iron concentrations in subjects (e.g. mice or humans), when administered thereto (e.g. parenterally injected or orally administered), in a dose-dependent and time-dependent manner. See e.g. as demonstrated in Rivera et al. (2005), Blood 106:2196-9.
- the peptides of the present invention have in vitro activity as assayed by the ability to cause the internalization and degradation of ferroportin in a ferroportin-expressing cell line as taught in Nemeth et al. (2006) Blood 107:328-33.
- In vitro activity may be measured by the dose-dependent loss of fluorescence of cells engineered to display ferroportin fused to green fluorescent protein as in Nemeth et al. (2006) Blood 107:328-33. Aliquots of cells are incubated for 24 hours with graded concentrations of a reference preparation of Hep25 or a mini-hepcidin.
- the EC50 values are provided as the concentration of a given compound (e.g.
- EC50 of Hep25 preparations in this assay range from 5 to 15 nM and preferred mini-hepcidins have EC50 values in in vitro activity assays of about 1,000 nM or less.
- the in vitro activity of compounds may be measured by their ability to internalize cellular ferroportin, which is determined by immunohistochemistry or flow cytometry using antibodies which recognizes extracellular epitopes of ferroportin.
- the in vitro activity of compounds may be measured by their dose- dependent ability to inhibit the efflux of iron from ferroportin-expressing cells that are preloaded with radioisotopes or stable isotopes of iron, as in Nemeth et al. (2006) Blood 107:328-33.
- Hep 1-9 and Hepl-10 C7A were found to be quite active in the flow-cytometry assay of ferroportin-GFP internalization.
- Hep 1-9 and Hepl-10 C7A were only about 4-times less potent and on a molar basis, about 10-times less potent than Hep25.
- Hepl- 9 and Hepl-10 C7A were used as the basis to construct other peptides having hepcidin activity.
- Hep 1-9 the C7 residue of Hep 1-9 was substituted with amino acids that have a similar shape but cannot form disulfide bonds to give Hep9-C7S (serine substitution) and Hep9C7-tBut (t-butyl-blocked cysteine) or with a cysteine modified by disulfide coupled tertiary butyl, which can participate in disulfide exchange with HS-t-butyl as the leaving group, to give Hep9C7-SStBut.
- amino acid substitutions that ablated the potential for disulfide formation or exchange caused a complete loss of hepcidin activity, thereby indicating that disulfide formation is required for activity.
- Other C7 amino acid substitutions and their resulting hepcidin activities are shown in Table 1.
- mini-hepcidins which exhibit ECso's of about 1000 nM or less contain at least 6 contiguous amino acid residues which correspond to residues 3-8 of Hep25 (see Hep3-8).
- preferred mini-hepcidins have at least 6 contiguous amino acid residues that correspond to 6 contiguous amino acid residues of Hep 1-9, preferably residues 3- 8.
- the amino acid residues may be unnatural or uncommon amino acids, L- or D- amino acid residues, modified residues, or a combination thereof.
- the mini-hepcidins of the present invention have at least one amino acid substitution, a modification, or an addition.
- amino acid substitutions include substituting an L-amino acid residue for its corresponding D-amino acid residue, substituting a Cys for homoC, Pen, (D)Pen, Inp, or the like, substituting Phe for bhPhe, Dpa, bhDpa, Bip, INaI, and the like.
- the names and the structures of the substituting residues are exemplified in Table 2.
- Other suitable substitutions are exemplified in Table 1.
- Examples of a modification include modifying one or more amino acid residues such that the peptide forms a cyclic structure, retroinversion, and modifying a residue to be capable of forming a disulfide bond.
- Examples of an addition include adding at least one amino acid residue or at least one compound to either the N-terminus, the C -terminus, or both such as that exemplified in Table 1.
- mini-hepcidins which exhibit ECso's of about 100 nM or less contain at least one Dpa or bhDPA amino acid substitution.
- the mini-hepcidins of the present invention have at least one Dpa or bhDPA amino acid substitution.
- the mini-hepcidins of the present invention may have an Ala at amino acid positions other than amino acid position 4 and 9 as long as there is an available thiol for forming a disulfide bond at amino acid position 7. See Hep9F4A and Hep9C-SStBut in Table 1.
- the mini-hepcidins of the present invention may have an amino acid substitution at position 4 which does not result in a substantial change of its charge or polarity as compared to that of Hep25, Hep 1-9 or Hepl-10 C7A.
- Preferred amino acid substitutions at position 4 of Hep 1-9 or Hepl-10 C7A include Phe, D-Phe, bhPhe, Dpa, bhDpa, Bip, INaI, or the like.
- mini-hepcidins according to the present invention have the following structural formula
- Al is Asp, GIu, pyroglutamate, GIn, Asn, or an unnatural amino acid commonly used as a substitute thereof;
- A2 is Thr, Ser, VaI, Ala, or an unnatural amino acid commonly used as a substitute thereof;
- A3 is His, Asn, Arg, or an unnatural amino acid commonly used as a substitute thereof;
- A4 is Phe, Leu, He, Trp, Tyr, or an unnatural amino acid commonly used as a substitute thereof which includes cyclohexylalanine;
- A5 is Pro, Ser, or an unnatural amino acid commonly used as a substitute thereof;
- A6 is He, Leu, VaI, or an unnatural amino acid commonly used as a substitute thereof;
- A7 is Cys, Ser, Ala, or an unnatural amino acid commonly used as a substitute thereof which includes S-tertiary butyl-cysteine;
- A8 is He, Leu, Thr, VaI, Arg, or an unnatural amino acid
- A6 is He; A7 is Ala; A8 is He; A9 is Phe; and AlO is Cys in amide form; wherein Al or Al to A2 are optionally absent.
- Al is Asp
- A2 is Thr
- A3 is His
- A4 is Phe
- A5 is Pro
- A6 is He
- A7 is Cys or an unnatural thiol amino acid
- A8 is He
- A9 is Phe in amide form
- AlO is absent.
- Al and A2 are absent, A3 is His, A4 is Phe, A5 is Pro,
- A6 is He
- A7 is Cys or an unnatural thiol amino acid
- A8 is He in amide form
- A9 and AlO are absent.
- Al and A2 are absent, A3 is His, A4 is Phe, A5 is Pro,
- A6 is He
- A7 is Cys or an unnatural thiol amino acid in amide form
- A8 to AlO are absent.
- the unnatural amino acid may be D-Asp, D-GIu, D-GIn, D-Asn, or the like. [80] In some embodiments, the unnatural amino acid for:
- Al is D-Asp, D-GIu, D-pyroglutamate, D-GIn, D-Asn, bbAsp, Ida, or N-
- A2 is D-Thr, D-Ser, D-VaI, Tie, Inp, Chg, bhThr, or N-MeThr;
- A3 is D-His, D-Asn, DArg, Dpa, (D)Dpa, or 2-aminoindan;
- A4 is D-Phe, D-Leu, D-IIe, D-Trp, Phg, bhPhe, Dpa, Bip, INaI, bhDpa, Amc,
- A5 is D-Pro, D-Ser, Oic, bhPro, trans-4-PhPro, cis-4-PhPro, cis-5-PhPro, Idc;
- A6 is D-IIe, D-Leu, Phg, Chg, Amc, bhlle, Ach, and MeIIe;
- A7 is D-Cys, D-Ser, D-AIa, Cys(S-tBut), homoC, Pen, (D)Pen, Dap(AcBr), and Inp;
- A8 is D-IIe, D-Leu, D-Thr, D-VaI, D-Arg, Chg, Dpa, bhlle, Ach, or MeIIe;
- A9 is D-Phe, D-Leu, D-IIe, PheF5, N-MePhe, benzylamide, bhPhe, Dpa, Bip, INaI, bhDpa, cyclohexylalanine; and
- AlO is D-Cys, D-Ser, D-AIa.
- amino acid substitution for:
- Al is Ala, D-AIa, Cys, D-Cys, Phe, D-Phe, Asp or D-Asp linked to Cys or D- Cys, Phe or D-Phe linked to a PEG molecule linked to chenodeoxycholate, ursodeoxycholate, or palmitoyl, or Dpa or (D)Dpa linked to palmitoyl;
- A2 is Ala, D-AIa, Cys, D-Cys, Pro, D-Pro, GIy, or D-GIy;
- A3 is Ala, D-AIa, Cys, D-Cys, Dpa, Asp or D-Asp linked to Dpa or (D)Dpa;
- A4 is Ala, D-AIa, Pro, or D-Pro;
- A5 is Ala, D-AIa, Pro, D-Pro, Arg, D-Arg;
- A6 is Ala, D-AIa, Phe, D-Phe, Arg, D-Arg, Cys, D-Cys;
- A7 is His, or D-His;
- A8 is Cys, or D-Cys; and
- A9 is Phe or D-Phe linked to RA, Asp, D-Asp, Asp or D-Asp linked to RB, bhPhe linked to RC, or cysteamide, wherein RA is -CONH 2 -CH 2 -CH 2 -S, -D-Pro linked to Pro-Lys or Pro-Arg, -bhPro linked to Pro linked to Pro- Lys or Pro-Arg, -D-Pro linked to bhPro-Lys or bhPro-Arg, wherein RB is -PEGU -GYIPEAPRDGQAYVRKDGEWVLLSTFL, -(PEGI l)- (GPHyp)lO, and wherein RC is -D-Pro linked to Pro-Lys or Pro-Arg, -D- Pro linked to bhPro-Lys or bhPro-Arg.
- the mini-hepcidin is a 10-mer sequence wherein A7 is
- the mini-hepcidin forms a cyclic structure by a disulfide bond.
- the mini-hepcidin is a retroinverted peptide such that
- the retroinverted peptide has at least one addition at the N-terminus, C-terminus, or both. In some embodiments, the retroinverted peptide contains at least one L-amino acid.
- the mini-hepcidin has an amino acid substitution at position 4, position 9, or both.
- the amino acid substituent is Phg, Phe, D-Phe, bhPhe, Dpa, Bip, INaI, Dpa, bhDpa, Amc, or cysteamide.
- the mini-hepcidin has an amino acid substitution at position 7.
- the amino acid substituent is Cys(S-tBut), Ala, D- AIa, Ser, D-Ser, homoC, Pen, (D)Pen, His, D-His, or Inp.
- R1 -CONH 2 -CH 2 -CH 2 -S
- R2 Chenodeoxycholate-(PEG11 )-
- R3 Ursodeoxycholate-(PEG1 1 )-
- R4 Palmitoyl-(PEG1 1 )-
- R5 2(Palmitoyl)-Dap(PEG11 )-
- Dap diaminopropionic acid
- R6 -PEG11-GYIPEAPRDGQAYVRKDGEWVLLSTFL
- Double underlined residues connected by a disulfide link to form a cyclized structure
- the PEG compound may be PEG11 , i.e. O- ⁇ -aminoethyQ-O'- ⁇ -carboxyethyQ-undecaethyleneglycol
- one or more peptides as described herein are provided in the form of a composition which comprises a carrier suitable for its intended purpose.
- the compositions may also include one or more additional ingredients suitable for its intended purpose.
- the compositions may comprise liposomes, niclosamide, SL220 solubilization agent (NOF, Japan), cremophor EL (Sigma), ethanol, and DMSO.
- the compositions may comprise different absorption enhancers and protease inhibitors, solid microparticles or nanoparticles for peptide encapsulation (such as chitosan and hydrogels), macromolecular conjugation, lipidization and other chemical modification.
- kits comprising one or more peptides and/or compositions of the present invention packaged together with reagents, devices, instructional material, or a combination thereof.
- the kits may include reagents used for conducting assays, drugs and compositions for diagnosing, treating, or monitoring disorders of iron metabolism, devices for obtaining samples to be assayed, devices for mixing reagents and conducting assays, and the like.
- the peptides of the present invention may be used to treat iron overload diseases.
- one or more peptides (preferably at least one mini-hepcidin) according to the present invention may be administered to a subject to ameliorate the symptoms and/or pathology associated with iron overload in iron-loading anemias (especially ⁇ - thalassemias) where phlebotomy is contraindicated and iron chelators are the mainstay of treatment but are often poorly tolerated.
- One or more peptides, preferably at least one mini-hepcidin, according to the present invention may be used to treat hereditary hemochromatosis, especially in subjects who do not tolerate maintenance phlebotomy.
- One or more peptides, preferably at least one mini- hepcidin, according to the present invention may be used to treat acute iron toxicity.
- one or more peptides of the present invention may be administered to a subject, preferably a mammal such as a human.
- the peptides are administered in a form of a pharmaceutical composition.
- the peptides are administered in a therapeutically effective amount.
- a "therapeutically effective amount” is an amount which ameliorates the symptoms and/or pathology of a given disease of iron metabolism as compared to a control such as a placebo.
- a therapeutically effective amount may be readily determined by standard methods known in the art.
- the dosages to be administered can be determined by one of ordinary skill in the art depending on the clinical severity of the disease, the age and weight of the subject, or the exposure of the subject to iron.
- Preferred effective amounts of the compounds of the invention ranges from about 0.01 to about 10 mg/kg body weight, preferably about 0.1 to about 3 mg/kg body weight, and more preferably about 0.5 to about 2 mg/kg body weight for parenteral formulations. Preferred effective amounts for oral administration would be up to about 10-fold higher.
- treatment of a subject with a peptide or composition of the present invention can include a single treatment or, preferably, can include a series of treatments. It will be appreciated that the actual dosages will vary according to the particular peptide or composition, the particular formulation, the mode of administration, and the particular site, host, and disease being treated. It will also be appreciated that the effective dosage used for treatment may increase or decrease over the course of a particular treatment.
- Optimal dosages for a given set of conditions may be ascertained by those skilled in the art using conventional dosage- determination tests in view of the experimental data for a given peptide or composition. Changes in dosage may result and become apparent by standard diagnostic assays known in the art. In some conditions chronic administration may be required.
- compositions of the invention may be prepared in a unit- dosage form appropriate for the desired mode of administration.
- the compositions of the present invention may be administered for therapy by any suitable route including oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous and intradermal). It will be appreciated that the preferred route will vary with the condition and age of the recipient, the nature of the condition to be treated, and the chosen peptide and composition.
- compositions of the present invention comprise a therapeutically effective amount of at least one peptide as disclosed herein, and an inert, pharmaceutically acceptable carrier or diluent.
- pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration and known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated.
- Supplementary active compounds can also be incorporated into the compositions.
- Supplementary active compounds include niclosamide, liposomes, SL220 solubilization agent (NOF, Japan), cremophor EL (Sigma), ethanol, and DMSO.
- Toxicity and therapeutic efficacy of the peptides and compositions of the present invention can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
- Peptides which exhibit large therapeutic indices are preferred. While peptides that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such peptides to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
- the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
- the dosage of peptides of the present invention lies preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
- IC50 i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms
- levels in plasma may be measured, for example, by high performance liquid chromatography.
- Hep25 was synthesized at the UCLA Peptide Synthesis Core Facility using solid phase 9-fluorenylmethyloxycarbonyl (fmoc) chemistry. Specifically, the peptides were synthesized on an ABI 43 IA peptide synthesizer (PE Biosystems, Applied Biosystems, Foster City, CA) using fmoc amino acids, Wang resin (AnaSpec, San Jose, CA), and double coupling for all residues.
- DTT dithiothreitol
- the reduced peptides were further purified by reversed-phase high-performance liquid chromatography (RP-HPLC) on VYDAC C18 column (218TP510; Waters) equilibrated with 0.1% trifluoroacetic acid and eluted with an acetonitrile gradient.
- the eluates were lyophilized, dissolved in 0.1% acetic acid, 20% DMSO, to the approximate concentration of 0.1 mg/ml (pH 8), and air oxidized by stirring for 18 hours at room temperature.
- the refolded peptides were also purified sequentially on the 10-g Cl 8 SEP-PAK cartridge and on the RP-HPLC VYDAC Cl 8 column using an acetonitrile gradient.
- the eluates were lyophilized and resuspended in 0.016% HCl.
- the conformation of refolded synthetic hepcidin derivatives was verified by electrophoresis in 12.5% acid-urea polyacrylamide gel electrophoresis (PAGE), and peptide masses were determined by matrix-assisted laser desorption/ionization time- of-flight mass spectrometry (MALDI-TOF-MS; UCLA Mass Spectrometry Facility, Los Angeles, CA).
- Peptides were cleaved from resin using modified reagent K (TFA 94% (v/v); phenol, 2% (w/v); water, 2% (v/v); TIS, 2% (v/v); 2 hours) and precipitated by addition of ice-cold diethyl ether.
- modified reagent K TIS 94% (v/v); phenol, 2% (w/v); water, 2% (v/v); TIS, 2% (v/v); 2 hours
- peptides were purified by preparative reverse-phase high performance liquid chromatography (RP- HPLC) to >95% homogeneity and their purity evaluated by matrix-assisted laser desorption ionization spectrometry (MALDI-MS, UCLA Mass Spectrometry Facility, Los Angeles, CA) as well as analytical RP-HPLC employing Varian ProStar 210 HPLC system equipped with ProStar 325 Dual Wavelength UV-Vis detector with the wavelengths set at 220 nm and 280 nm (Varian Inc., Palo Alto, CA).
- Mobile phases consisted of solvent A, 0.1% TFA in water, and solvent B, 0.1% TFA in acetonitrile.
- FLOW CYTOMETRY The activity of peptides of the present invention was measured by flow cytometry as previously described. See Nemeth et al. (2006) Blood 107:328-333, which is herein incorporated by reference. ECR293/Fpn-GFP, a cell line stably transfected with a ponasterone-inducible ferroportin construct tagged at the C-terminus with green fluorescent protein was used. See Nemeth et al. (2004) Science 306:2090-2093, which is herein incorporated by reference. Briefly, the cells were plated on poly-D-lysine coated plates in the presence of 20 ⁇ M FAC, with or without 10 ⁇ M ponasterone.
- ponasterone was washed off, and cells were treated with peptides for 24 hours. Cells were then trypsinized and resuspended at 1 x 10 6 cells/ml, and the intensity of green fluorescence was analyzed by flow cytometry. Flow cytometry was performed onFACSCAN (fluorescence activated cell scanner) Analytic Flow Cytometer (Becton Dickinson, San Jose, CA) with CELLQUEST version 3.3 software (Becton Dickinson). Cells not induced with ponasterone to express Fpn- GFP were used to establish a gate to exclude background fluorescence. Cells induced with ponasterone, but not treated with any peptides, were used as the positive control.
- Each peptide was tested over the range of concentrations (0, 0.01, 0.03, 0.1, 0.3, 1, 3 and 10 ⁇ M). Each peptide treatment was repeated independently 3 to 6 times. For each concentration of peptide, the results were expressed as a fraction of the maximal activity (F ⁇ e p25) of Hep25 (in the dose range 0.01-10 ⁇ M), according to the formula 1 - ((F x - F Hep 25) / (Funtreated - F Hep 25)), where F was the mean of the gated green fluorescence and x was the peptide.
- the IEC50 concentrations are set forth in the Table 1.
- FERRITIN ASSAY Cells treated with peptides having hepcidin activity will retain iron and contain higher amounts of ferritin. Thus, following ferritin assay may be used to identify mini-hepcidins according to the present invention. Briefly, HEK293-Fpn cells are incubated with 20 ⁇ M FAC with or without 10 ⁇ M ponasterone. After 24 hours, ponasterone is washed off, and hepcidin derivatives are added for 24 hours in the presence of 20 ⁇ M FAC.
- Cellular protein is extracted with 150 mM NaCl, 10 mM EDTA, 10 mM Tris (pH 7.4), 1% Triton X- 100, and a protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO).
- Ferritin levels are determined by an enzyme-linked immunosorbent assay (ELISA) assay (Ramco Laboratories, Stafford, TX, or Biotech Diagnostic, Website Niguel, CA) according to the manufacturer's instructions and are normalized for the total protein concentration in each sample, as determined by the bicinchoninic acid (BCA) assay (Pierce, Rockford, IL).
- ELISA enzyme-linked immunosorbent assay
- Peptide stocks were diluted to desired concentrations in sterile phosphate buffered saline (PBS) or other diluents as described next. Mice were subjected to the following treatments: (a) Injected intraperitoneally either with 100 ⁇ l PBS (control) or with 50 ⁇ g peptide in 100 ⁇ l PBS; (b) Injected with 100 ⁇ l of peptide (or PBS) mixed with 500 ⁇ g empty liposomes COATSOME EL series (NOF, Tokyo, Japan) (prepared as per manufacturer's recommendation); (c) Injected with 100 ⁇ l peptides (or PBS) solubilized with SL220 solubilization agent (NOF, Tokyo, Japan); (d) Gavaged with 250 ⁇ l of peptide (or PBS) in Ix solvent (Cremophor EL (Sigma)/ethanol/PBS; (12.5:12.5:75)).
- mice were sacrificed 4 hours later, blood was collected by cardiac puncture, and serum was separated using MICROTAINER tubes (Becton Dickinson, Franklin Lakes, NJ). Serum iron was determined by using a colorimetric assay (Diagnostic Chemicals, Oxford, CT), which was modified for the microplate format so that 10 ⁇ l serum was used per measurement. The results were expressed as the percentage of decrease in serum iron when compared with the average value of serum iron levels in PBS-treated mice.
- i.p. administration of 20 nmoles Pr27 in liposomal solution also caused a serum iron decrease similar to that caused by i.p. administration of 20 nmoles Hep25.
- Administration of liposomal solution by itself did not affect serum iron levels.
- the liposomal solution was prepared by mixing 100 ⁇ l of PBS with 500 ⁇ g empty liposomes COATSOME EL series (NOF, Tokyo, Japan) (prepared as per manufacturer's recommendation).
- Mini-hepcidin Pr28 dissolved in liposomal solution showed lesser ability to decrease serum iron than Pr27. The experiment indicates that suspension of peptides in liposomes does not affect their activity.
- liposomes may be useful for oral administration of peptides according to the present invention.
- a preferred mini-hepcidin according to the present invention is a retroinverted peptide which comprises a PEG molecule, such as PEGl 1, linked to its N-terminal amino acid.
- the PEG molecule is linked to palmitoyl group or diaminopropionic acid linked to one or more palmitoyl groups.
- mini-hepcidins In addition to assaying the effect on serum iron content, other in vivo assays known in the art may be conducted to identify mini-hepcidins according to the present invention and/or determine the therapeutically effective amount of a given peptide or mini-hepcidin according to the present invention. Examples of such assays include the following:
- tissue iron assay In addition to or instead of the serum iron assay above, tissue iron distribution can be determined by enhanced Perl's stain of liver and spleen sections obtained from the treated mice. Briefly, the tissue sections are fixed in 4% paraformaldehyde/PBS, incubated in Perl's solution (1 :1, 2% HCl and 2% potassium ferrocyanide) and diaminobenzidine in 0.015% hydrogen peroxide. Tissue non-heme iron may be quantitated using the micromethod of Rebouche et al. See Rebouche et al, J Biochem Biophys Methods. 2004 Mar 31;58(3):239-51.; Pak et al. Blood.
- Hematology assays may be used to identify mini- hepcidins according to the present invention and/or determine the therapeutically effective amount of a given peptide or mini-hepcidin according to the present invention. Briefly, blood from treated subjects is collected into heparin-containing tubes. Hemoglobin, RBC, MCV, EPO, white cell parameters, reticulocyte counts, and reticulocyte Hgb content are determined using methods known in the art and compared to controls. Treatment with mini-hepcidins would be expected to cause a decrease in MCV and diminish the Hgb content of reticulocytes. Administration of mini-hepcidins in excessive amounts would be expected to decrease Hgb.
- IRON EXPORT ASSAYS Iron ( 55 Fe) export assays known in the art using primary hepatocytes and macrophages may be used to identify mini-hepcidins according to the present invention and/or determine the therapeutically effective amount of a given peptide or mini-hepcidin according to the present invention. Peptides having hepcidin activity will diminish or decrease the release Of 55 Fe from cells. Briefly, cells are incubated with 55 Fe-NTA or 55 Fe-Tf for 36 hours. After washing off unincorporated 55 Fe, cells are treated with a given peptide or a control. In case of ferroportin mutants, the transfection is performed prior to addition Of 55 Fe and expression allowed to proceed during the 36 hour iron- loading period.
- Radioactivity is determined by a scintillation counter.
- Cell-associated radioactivity can be measured by centrifuging cells through silicone oil to lower the non-specific binding of radiolabeled iron to cells using methods known in the art.
- the protein levels and cellular distribution of ferroportin in hepatocytes and macrophages treated with the peptide may be assayed using Western blotting, immunohistochemistry and ferroportin antibodies known in the art.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009322260A AU2009322260B2 (en) | 2008-12-05 | 2009-12-04 | Mini-hepcidin peptides and methods of using thereof |
BRPI0922708A BRPI0922708A2 (en) | 2008-12-05 | 2009-12-04 | minihepidine peptides and methods of use thereof |
EP09831165.7A EP2373679B1 (en) | 2008-12-05 | 2009-12-04 | Mini-hepcidin peptides and methods of using thereof |
CN2009801489671A CN102245626A (en) | 2008-12-05 | 2009-12-04 | Mini-hepcidin peptides and methods of using thereof |
EP17159667.9A EP3208279B1 (en) | 2008-12-05 | 2009-12-04 | Mini-hepcidin peptides and methods of using thereof |
US13/131,792 US8435941B2 (en) | 2008-12-05 | 2009-12-04 | Mini-hepcidin peptides and methods of using thereof |
US13/793,116 US20130203662A1 (en) | 2008-12-05 | 2013-03-11 | Mini-Hepcidin Peptides and Methods of Using Thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12027708P | 2008-12-05 | 2008-12-05 | |
US61/120,277 | 2008-12-05 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/793,116 Continuation US20130203662A1 (en) | 2008-12-05 | 2013-03-11 | Mini-Hepcidin Peptides and Methods of Using Thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010065815A2 true WO2010065815A2 (en) | 2010-06-10 |
WO2010065815A3 WO2010065815A3 (en) | 2010-10-21 |
Family
ID=42233878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/066711 WO2010065815A2 (en) | 2008-12-05 | 2009-12-04 | Mini-hepcidin peptides and methods of using thereof |
Country Status (6)
Country | Link |
---|---|
US (2) | US8435941B2 (en) |
EP (2) | EP2373679B1 (en) |
CN (1) | CN102245626A (en) |
AU (1) | AU2009322260B2 (en) |
BR (1) | BRPI0922708A2 (en) |
WO (1) | WO2010065815A2 (en) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101955525A (en) * | 2010-07-13 | 2011-01-26 | 中国农业科学院兰州畜牧与兽药研究所 | Artificial antimicrobial peptide, gene and preparation method thereof |
WO2013086143A1 (en) | 2011-12-09 | 2013-06-13 | The Regents Of The University Of California | Modified mini-hepcidin peptides and methods of using thereof |
WO2014147246A1 (en) | 2013-03-21 | 2014-09-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression |
EP2668497A4 (en) * | 2011-01-26 | 2015-09-16 | Univ Pittsburgh | Urine biomarkers for prediction of recovery after acute kidney injury : proteomics |
WO2015157283A1 (en) * | 2014-04-07 | 2015-10-15 | Merganser Biotech Llc | Hepdicin mimetic peptides and uses thereof |
US9234903B2 (en) | 2001-05-25 | 2016-01-12 | INSERM (Institut National de la Santé et de la Recherche Médicale | Hepcidin inhibitors for regulating iron homeostasis |
KR20160005332A (en) * | 2013-03-15 | 2016-01-14 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | Hepcidin analogues and uses therof |
CN105263514A (en) * | 2013-03-15 | 2016-01-20 | 本质生命科学有限公司 | Anti-hepcidin antibodies and uses thereof |
WO2016109363A1 (en) | 2014-12-29 | 2016-07-07 | The Regents Of The University Of California | S-Alkylated Hepcidin Peptides and Methods of Making and Using Thereof |
WO2018048944A1 (en) * | 2016-09-06 | 2018-03-15 | La Jolla Pharmceutical Company | Methods of treating iron overload |
EP3161164A4 (en) * | 2014-06-27 | 2018-04-25 | Protagonist Therapeutics Inc. | Hepcidin and mini-hepcidin analogues and uses therof |
WO2018107241A1 (en) * | 2016-12-16 | 2018-06-21 | The University Of Sydney | Treatment of iron disorders |
WO2018128828A1 (en) | 2016-12-23 | 2018-07-12 | Bayer Healthcare Llc | Novel hepcidin mimetics and uses thereof |
US10023614B2 (en) | 2014-07-17 | 2018-07-17 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
US10059744B2 (en) | 2014-05-16 | 2018-08-28 | Protagonist Therapeutics, Inc. | α4β7 thioether peptide dimer antagonists |
WO2018175633A1 (en) * | 2017-03-22 | 2018-09-27 | La Jolla Pharmaceutical Company | Methods of inducing anti-malarial immune responses and compositions related thereto |
US10278957B2 (en) | 2017-09-11 | 2019-05-07 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
US10301371B2 (en) | 2014-10-01 | 2019-05-28 | Protagonist Therapeutics, Inc. | Cyclic monomer and dimer peptides having integrin antagonist activity |
US10323088B2 (en) | 2014-09-22 | 2019-06-18 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
EP3399996A4 (en) * | 2016-01-08 | 2019-10-16 | La Jolla Pharmaceutical Company | Methods of administering hepcidin |
WO2020123850A1 (en) | 2018-12-13 | 2020-06-18 | Global Blood Therapeutics, Inc. | Ferroportin inhibitors and methods of use |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
US11041000B2 (en) | 2019-07-10 | 2021-06-22 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
US11111272B2 (en) | 2014-10-01 | 2021-09-07 | Protagonist Therapeutics, Inc. | α4α7 peptide monomer and dimer antagonists |
WO2021222359A1 (en) | 2020-04-28 | 2021-11-04 | Global Blood Therapeutics, Inc. | Thieno pyrimidines as ferroportin inhibitors |
WO2021222483A1 (en) | 2020-04-28 | 2021-11-04 | Global Blood Therapeutics, Inc. | Methods of use for pyrimidines as ferroportin inhibitors |
WO2021222363A1 (en) | 2020-04-28 | 2021-11-04 | Global Blood Therapeutics, Inc. | Cycloalkyl pyrimidines as ferroportin inhibitors |
WO2022003238A1 (en) * | 2020-07-02 | 2022-01-06 | Tampere University Foundation Sr | Renin-based analysis of hepcidin |
US11472842B2 (en) | 2015-12-30 | 2022-10-18 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
US11753443B2 (en) | 2018-02-08 | 2023-09-12 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
US11845808B2 (en) | 2020-01-15 | 2023-12-19 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
US11939361B2 (en) | 2020-11-20 | 2024-03-26 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of Interleukin-23 receptor |
US12018057B2 (en) | 2020-01-15 | 2024-06-25 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8435941B2 (en) * | 2008-12-05 | 2013-05-07 | The Regents Of The University Of California | Mini-hepcidin peptides and methods of using thereof |
ES2731609T3 (en) * | 2012-11-01 | 2019-11-18 | Univ California | ERFE and erythroferrone polypeptides and iron metabolism regulation methods |
GB201302837D0 (en) * | 2013-02-19 | 2013-04-03 | Univ Singapore | Therapeutic Agents |
US10407468B2 (en) | 2016-03-23 | 2019-09-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing α4β7 peptide antagonists |
CN109983029A (en) * | 2016-08-05 | 2019-07-05 | 西拉鲁思治疗公司 | ERFE specific antibody composition and application method |
JPWO2022154121A1 (en) * | 2021-01-18 | 2022-07-21 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004092405A2 (en) | 2003-04-15 | 2004-10-28 | Xenon Pharmaceuticals Inc. | Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof |
US7534764B2 (en) | 2005-06-29 | 2009-05-19 | The Regents Of The University Of California | Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993025577A2 (en) * | 1992-06-12 | 1993-12-23 | Zenyaku Kogyo Co., Ltd. | Active component of parathyroid hypertensive factor |
JP2891023B2 (en) * | 1993-03-09 | 1999-05-17 | 味の素株式会社 | Method for producing lanthionine-containing material |
DE10228103A1 (en) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungicidal active ingredient combinations |
JP4638350B2 (en) | 2002-11-19 | 2011-02-23 | ディーアールジー・インターナショナル,インコーポレイテッド | Method for detecting the presence or amount of hepcidin in human or animal tissues, blood or body fluids |
PE20130588A1 (en) | 2007-02-02 | 2013-05-21 | Amgen Inc | HEPCIDIN, HEPCIDIN ANTAGONISTS AND METHODS OF USE |
US8435941B2 (en) * | 2008-12-05 | 2013-05-07 | The Regents Of The University Of California | Mini-hepcidin peptides and methods of using thereof |
AU2012327226C1 (en) * | 2011-12-09 | 2017-03-02 | The Regents Of The University Of California | Modified mini-hepcidin peptides and methods of using thereof |
-
2009
- 2009-12-04 US US13/131,792 patent/US8435941B2/en not_active Expired - Fee Related
- 2009-12-04 BR BRPI0922708A patent/BRPI0922708A2/en not_active IP Right Cessation
- 2009-12-04 CN CN2009801489671A patent/CN102245626A/en active Pending
- 2009-12-04 AU AU2009322260A patent/AU2009322260B2/en not_active Expired - Fee Related
- 2009-12-04 EP EP09831165.7A patent/EP2373679B1/en not_active Not-in-force
- 2009-12-04 EP EP17159667.9A patent/EP3208279B1/en active Active
- 2009-12-04 WO PCT/US2009/066711 patent/WO2010065815A2/en active Application Filing
-
2013
- 2013-03-11 US US13/793,116 patent/US20130203662A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004092405A2 (en) | 2003-04-15 | 2004-10-28 | Xenon Pharmaceuticals Inc. | Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof |
US7534764B2 (en) | 2005-06-29 | 2009-05-19 | The Regents Of The University Of California | Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin |
Non-Patent Citations (17)
Title |
---|
HOUGHTEN, PNAS USA, vol. 82, 1985, pages 5131 - 5135 |
ILYIN, G. ET AL., FEBS LETT., vol. 542, 2003, pages 22 - 26 |
JORDAN ET AL., J BIOL CHEM, vol. 284, 2009, pages 24155 - 67 |
KELLY; WINKLER: "Genetic Engineering Principles and Methods", vol. 12, 1990, PLENUM PRESS, pages: 1 - 19 |
KRAUSE ET AL., FEBS LETT, vol. 480, 2000, pages 147 - 150 |
MERRIFIELD, J AMER CHEM SOC, vol. 85, 1964, pages 2149 |
NEMETH ET AL., BLOOD, vol. 107, 2006, pages 328 - 33 |
NEMETH ET AL., BLOOD, vol. 107, 2006, pages 328 - 333 |
NEMETH ET AL., SCIENCE, vol. 306, 2004, pages 2090 - 2093 |
OLSNES, S.; A. PIHL, BIOCHEM., vol. 12, no. 16, 1973, pages 3121 - 3126 |
PAK ET AL., BLOOD, vol. 108, no. 12, 1 December 2006 (2006-12-01), pages 3730 - 5 |
PARK ET AL., J BIOL CHEM, vol. 276, 2001, pages 7806 - 7810 |
REBOUCHE ET AL., J BIOCHEM BIOPHYS METHODS, vol. 58, no. 3, 31 March 2004 (2004-03-31), pages 239 - 51 |
RIVERA ET AL., BLOOD, vol. 106, 2005, pages 2196 - 9 |
SCOPES: "Protein Purification", 1982, SPRINGER-VERLAG |
See also references of EP2373679A4 |
STEWART; YOUNG: "Solid Phase Peptide Synthesis", 1984, PIERCE |
Cited By (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1392345B2 (en) † | 2001-05-25 | 2018-02-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis |
US9782453B2 (en) | 2001-05-25 | 2017-10-10 | Institut National De La Sante Et De La Recherche Medicale | Use of hepcidin as a regulator of iron homeostasis |
US9234903B2 (en) | 2001-05-25 | 2016-01-12 | INSERM (Institut National de la Santé et de la Recherche Médicale | Hepcidin inhibitors for regulating iron homeostasis |
US10004784B2 (en) | 2001-05-25 | 2018-06-26 | Institut National De La Sante Et De La Recherche Medicale | Use of hepcidin as a regulator of iron homeostasis |
US9896481B2 (en) | 2008-12-05 | 2018-02-20 | The Regents Of The University Of California | Modified mini-hepcidin peptides and methods of using thereof |
US20140336110A1 (en) * | 2008-12-05 | 2014-11-13 | The Regents Of The University Of California | Modified Mini-Hepcidin Peptides and Methods of Using Thereof |
US9328140B2 (en) | 2008-12-05 | 2016-05-03 | The Regents Of The University Of California | Modified mini-hepcidin peptides and methods of using thereof |
CN101955525A (en) * | 2010-07-13 | 2011-01-26 | 中国农业科学院兰州畜牧与兽药研究所 | Artificial antimicrobial peptide, gene and preparation method thereof |
EP2668497A4 (en) * | 2011-01-26 | 2015-09-16 | Univ Pittsburgh | Urine biomarkers for prediction of recovery after acute kidney injury : proteomics |
JP2018087215A (en) * | 2011-12-09 | 2018-06-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Modified mini-hepcidin peptides and methods of using the same |
AU2012327226B2 (en) * | 2011-12-09 | 2016-04-14 | The Regents Of The University Of California | Modified mini-hepcidin peptides and methods of using thereof |
AU2012327226C9 (en) * | 2011-12-09 | 2017-02-16 | The Regents Of The University Of California | Modified mini-hepcidin peptides and methods of using thereof |
WO2013086143A1 (en) | 2011-12-09 | 2013-06-13 | The Regents Of The University Of California | Modified mini-hepcidin peptides and methods of using thereof |
JP2015504859A (en) * | 2011-12-09 | 2015-02-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Modified minihepcidin peptides and methods of use thereof |
AU2012327226C1 (en) * | 2011-12-09 | 2017-03-02 | The Regents Of The University Of California | Modified mini-hepcidin peptides and methods of using thereof |
US9803011B2 (en) | 2013-03-15 | 2017-10-31 | Intrinsic Lifesciences Llc | Anti-hepcidin antibodies and uses thereof |
JP2019037236A (en) * | 2013-03-15 | 2019-03-14 | イントリンシック ライフサイエンシズ リミテッド ライアビリティ カンパニー | Anti-hepcidin antibodies and uses thereof |
CN105263514B (en) * | 2013-03-15 | 2019-04-26 | 本质生命科学有限公司 | Anti- hepcidin antibody and application thereof |
US9657098B2 (en) | 2013-03-15 | 2017-05-23 | Intrinsic Lifesciences, Llc | Anti-hepcidin antibodies and uses thereof |
JP2016513664A (en) * | 2013-03-15 | 2016-05-16 | イントリンシック ライフサイエンシズ リミテッド ライアビリティ カンパニー | Anti-hepcidin antibodies and uses thereof |
US10442846B2 (en) | 2013-03-15 | 2019-10-15 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
US10239941B2 (en) | 2013-03-15 | 2019-03-26 | Intrinsic Lifesciences Llc | Anti-hepcidin antibodies and uses thereof |
CN105263514A (en) * | 2013-03-15 | 2016-01-20 | 本质生命科学有限公司 | Anti-hepcidin antibodies and uses thereof |
US11807674B2 (en) | 2013-03-15 | 2023-11-07 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
AU2018214008B2 (en) * | 2013-03-15 | 2019-12-12 | Intrinsic Lifesciences Llc | Anti-hepcidin antibodies and uses thereof |
EP4091624A1 (en) * | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
KR20160005332A (en) * | 2013-03-15 | 2016-01-14 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | Hepcidin analogues and uses therof |
KR102236829B1 (en) * | 2013-03-15 | 2021-04-07 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | Hepcidin analogues and uses therof |
EP2968503A4 (en) * | 2013-03-15 | 2017-02-15 | Intrinsic Lifesciences LLC | Anti-hepcidin antibodies and uses thereof |
AU2014236677B2 (en) * | 2013-03-15 | 2018-07-05 | Intrinsic Lifesciences Llc | Anti-hepcidin antibodies and uses thereof |
US10501515B2 (en) | 2013-03-15 | 2019-12-10 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
AU2018260800B2 (en) * | 2013-03-15 | 2020-04-09 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses therof |
US10030061B2 (en) | 2013-03-15 | 2018-07-24 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
WO2014147246A1 (en) | 2013-03-21 | 2014-09-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression |
WO2015157283A1 (en) * | 2014-04-07 | 2015-10-15 | Merganser Biotech Llc | Hepdicin mimetic peptides and uses thereof |
US9315545B2 (en) | 2014-04-07 | 2016-04-19 | Merganser Biotech, Inc. | Hepcidin mimetic peptides and uses thereof |
US10059744B2 (en) | 2014-05-16 | 2018-08-28 | Protagonist Therapeutics, Inc. | α4β7 thioether peptide dimer antagonists |
US10626146B2 (en) | 2014-05-16 | 2020-04-21 | Protagonist Therapeutics, Inc. | α4β7 thioether peptide dimer antagonists |
US11840581B2 (en) | 2014-05-16 | 2023-12-12 | Protagonist Therapeutics, Inc. | α4β7 thioether peptide dimer antagonists |
EP3161164A4 (en) * | 2014-06-27 | 2018-04-25 | Protagonist Therapeutics Inc. | Hepcidin and mini-hepcidin analogues and uses therof |
US10035824B2 (en) | 2014-07-17 | 2018-07-31 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
US10941183B2 (en) | 2014-07-17 | 2021-03-09 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
US11884748B2 (en) | 2014-07-17 | 2024-01-30 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
US10196424B2 (en) | 2014-07-17 | 2019-02-05 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
US10023614B2 (en) | 2014-07-17 | 2018-07-17 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
US10323088B2 (en) | 2014-09-22 | 2019-06-18 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
US10301371B2 (en) | 2014-10-01 | 2019-05-28 | Protagonist Therapeutics, Inc. | Cyclic monomer and dimer peptides having integrin antagonist activity |
US11111272B2 (en) | 2014-10-01 | 2021-09-07 | Protagonist Therapeutics, Inc. | α4α7 peptide monomer and dimer antagonists |
EP3240799A4 (en) * | 2014-12-29 | 2018-05-09 | The Regents of the University of California | S-alkylated hepcidin peptides and methods of making and using thereof |
WO2016109363A1 (en) | 2014-12-29 | 2016-07-07 | The Regents Of The University Of California | S-Alkylated Hepcidin Peptides and Methods of Making and Using Thereof |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
US11472842B2 (en) | 2015-12-30 | 2022-10-18 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
EP3399996A4 (en) * | 2016-01-08 | 2019-10-16 | La Jolla Pharmaceutical Company | Methods of administering hepcidin |
WO2018048944A1 (en) * | 2016-09-06 | 2018-03-15 | La Jolla Pharmceutical Company | Methods of treating iron overload |
WO2018107241A1 (en) * | 2016-12-16 | 2018-06-21 | The University Of Sydney | Treatment of iron disorders |
WO2018128828A1 (en) | 2016-12-23 | 2018-07-12 | Bayer Healthcare Llc | Novel hepcidin mimetics and uses thereof |
WO2018175633A1 (en) * | 2017-03-22 | 2018-09-27 | La Jolla Pharmaceutical Company | Methods of inducing anti-malarial immune responses and compositions related thereto |
US10278957B2 (en) | 2017-09-11 | 2019-05-07 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
US10729676B2 (en) | 2017-09-11 | 2020-08-04 | Protagonist Theraputics, Inc. | Opioid agonist peptides and uses thereof |
US11753443B2 (en) | 2018-02-08 | 2023-09-12 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
WO2020123850A1 (en) | 2018-12-13 | 2020-06-18 | Global Blood Therapeutics, Inc. | Ferroportin inhibitors and methods of use |
US11286243B2 (en) | 2018-12-13 | 2022-03-29 | Global Blood Therapeutics, Inc. | Ferroportin inhibitors and methods of use |
US11041000B2 (en) | 2019-07-10 | 2021-06-22 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
US11845808B2 (en) | 2020-01-15 | 2023-12-19 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
US12018057B2 (en) | 2020-01-15 | 2024-06-25 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
US11746100B2 (en) | 2020-04-28 | 2023-09-05 | Global Blood Therapeutics, Inc. | Cycloalkyl pyrimidines as ferroportin inhibitors |
WO2021222363A1 (en) | 2020-04-28 | 2021-11-04 | Global Blood Therapeutics, Inc. | Cycloalkyl pyrimidines as ferroportin inhibitors |
WO2021222483A1 (en) | 2020-04-28 | 2021-11-04 | Global Blood Therapeutics, Inc. | Methods of use for pyrimidines as ferroportin inhibitors |
WO2021222359A1 (en) | 2020-04-28 | 2021-11-04 | Global Blood Therapeutics, Inc. | Thieno pyrimidines as ferroportin inhibitors |
WO2022003238A1 (en) * | 2020-07-02 | 2022-01-06 | Tampere University Foundation Sr | Renin-based analysis of hepcidin |
US11939361B2 (en) | 2020-11-20 | 2024-03-26 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of Interleukin-23 receptor |
Also Published As
Publication number | Publication date |
---|---|
EP3208279A1 (en) | 2017-08-23 |
EP3208279B1 (en) | 2021-04-21 |
EP2373679B1 (en) | 2017-03-08 |
EP2373679A4 (en) | 2012-05-30 |
WO2010065815A3 (en) | 2010-10-21 |
US8435941B2 (en) | 2013-05-07 |
AU2009322260A1 (en) | 2011-07-07 |
BRPI0922708A2 (en) | 2018-11-06 |
AU2009322260B2 (en) | 2013-09-12 |
EP2373679A2 (en) | 2011-10-12 |
US20130203662A1 (en) | 2013-08-08 |
US20120040894A1 (en) | 2012-02-16 |
CN102245626A (en) | 2011-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2373679B1 (en) | Mini-hepcidin peptides and methods of using thereof | |
AU2012327226C9 (en) | Modified mini-hepcidin peptides and methods of using thereof | |
US11807674B2 (en) | Hepcidin analogues and uses thereof | |
EP3240799B1 (en) | S-alkylated hepcidin peptides and methods of making and using thereof | |
Vine et al. | Synthesis of fluorine-containing peptides. Analogs of angiotensin II containing hexafluorovaline | |
NZ751741B2 (en) | Hepcidin analogues and uses therof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980148967.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09831165 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13131792 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009322260 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5001/DELNP/2011 Country of ref document: IN |
|
REEP | Request for entry into the european phase |
Ref document number: 2009831165 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009831165 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009322260 Country of ref document: AU Date of ref document: 20091204 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0922708 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110606 |